Journal profile · Multiple
Journal of Dual Diagnosis
ISSN 1550-4263 · eISSN 1550-4271 · Taylor & Francis
Journal of Dual Diagnosis: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.58; hybrid open access; APC charged, amount not published; review about 54 days (first decision after review, publisher); acceptance rate 39% (journal website); 32 articles in 2025; indexed in SSCI and Scopus.
Scope
Aims, scope and focus
Journal of Dual Diagnosis is published by Taylor & Francis and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Substance Abuse Treatment and Outcomes, Schizophrenia research and treatment and Smoking Behavior and Cessation, together about 35.2% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Journal of Dual Diagnosis is a quarterly, international publication that focuses on the full spectrum of complexities regarding dual diagnosis. The co-occurrence of mental health and substance use disorders, or “dual diagnosis,” is one of the quintessential issues in behavioral health. Why do such high rates of co-occurrence exist? What does it tell us about risk profiles? How do these linked disorders affect people, their families, and the communities in which they live? What are the natural paths to recovery? What specific treatments are most helpful and how can new ones be developed? How can we enhance the implementation of evidence-based practices at clinical, administrative, and policy levels? How can we help clients to learn active recovery skills and adopt needed supports, clinicians to master new interventions, programs to implement effective services, and communities to foster healthy adjustment? The Journal addresses each of these perplexing challenges. Journal of Dual Diagnosis includes articles and perspectives from four overarching domains relevant to the field: Psychopharmacology & Neurobiology; Psychotherapy & Psychosocial Issues; Services & Policy; and Clinical Forum. Each issue serves to encourage integration of these domains. The Journal seeks to publish articles relevant to a wide range of people interested in dual diagnosis: researchers, physicians, clinicians, trainees, administrators, and policy makers. High-quality empirical research, brief reports, timely reviews, thought-provoking commentaries, and ongoing discussions of clinical issues will be considered for publication, all with the aim of developing a better understanding of the basis of, and optimal treatment for, co-occurring psychiatric and substance use disorders.
From the journal's Aims & Scope
Research area (LetPub): Multiple
Editor-in-chief E. Sherwood BrownPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Substance Abuse Treatment and OutcomesMedicine19%
- Schizophrenia research and treatmentMedicine9.5%
- Smoking Behavior and CessationMedicine6.7%
- Mental Health Treatment and AccessPsychology6.7%
- Posttraumatic Stress Disorder ResearchPsychology5.8%
- Opioid Use Disorder TreatmentMedicine5.1%
- Homelessness and Social IssuesHealth Professions4.2%
- Child and Adolescent Psychosocial and Emotional DevelopmentPsychology3.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Psychiatry | Zone 4 |
| Minor | Psychology, Clinical | Zone 4 |
| Minor | Substance Abuse | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Psychology, Clinical | Zone 2 |
| Minor | Substance Abuse | Zone 2 |
| Minor | Psychiatry | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Psychiatry | Zone 4 |
| Minor | Psychology, Clinical | Zone 4 |
| Minor | Substance Abuse | Zone 4 |
Top journal: noReview journal: no
Database indexing
SSCIScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PubMedEmbasePsycINFOPublisher website
Other: ProQuest, E-Psyche, EBSCOhost, Clarivate Analytics, Adis International Ltd.
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.58LetPub ·
- Impact factor (publisher) 2025
- 1.5Publisher website ·
- 5-year impact factor (publisher) 2025
- 2Publisher website ·
- CiteScore 2026-06
- 3LetPub ·
- CiteScore (publisher) 2025
- 3Publisher website ·
- SJR 2026-06
- 0.57LetPub ·
- SJR (publisher) 2025
- 0.57Publisher website ·
- SNIP 2026-06
- 0.72LetPub ·
- SNIP (publisher) 2025
- 0.72Publisher website ·
- h-index
- 45OpenAlex ·
- i10-index
- 300OpenAlex ·
- 2-year mean citedness
- 1.18OpenAlex ·
- Self-citation rate
- 13.3%LetPub ·
- Share of gold OA articles
- 5.95%LetPub ·
Volume
- Articles per year
- 32LetPub ·
- Downloads per year (publisher)
- 52,000Publisher website ·
- Downloads per year (publisher) 2025
- 52,000Publisher website ·
Articles by year OpenAlex count · 806 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 33 | 6 | 3 |
| 2025 | 32 | 14 | 41 |
| 2024 | 34 | 12 | 73 |
| 2023 | 25 | 11 | 189 |
| 2022 | 25 | 12 | 194 |
| 2021 | 32 | 15 | 263 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Publisher-reported review time from the journal's website
54 daysfirst decision after review
The publisher's own definition applies; dates from this journal's articles in the last 24 months are not available yet, so the publisher's figure is used.
Figures by source
- Acceptance rate (publisher)
- 39%Publisher website ·
- Acceptance rate (publisher) 2025
- 39%Publisher website ·
- Submission to first decision
- 42 daysPublisher website ·
- Submission to first decision 2025
- 42 daysPublisher website ·
- First decision after review
- 54 daysPublisher website ·
- First decision after review 2025
- 54 daysPublisher website ·
- Acceptance to publication
- 205 daysPublisher website ·
- Acceptance to publication 2025
- 205 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | Yes, amount not published | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted5
- brief reportsHigh-quality empirical research, brief reports, timely reviews, thought-provoking commentaries, and ongoing discussions of clinical issues will be considered fo…Length not stated
- high-quality empirical researchHigh-quality empirical research, brief reports, timely reviews, thought-provoking commentaries, and ongoing discussions of clinical issues will be considered fo…Length not stated
- ongoing discussions of clinical issuesHigh-quality empirical research, brief reports, timely reviews, thought-provoking commentaries, and ongoing discussions of clinical issues will be considered fo…Length not stated
- thought-provoking commentariesHigh-quality empirical research, brief reports, timely reviews, thought-provoking commentaries, and ongoing discussions of clinical issues will be considered fo…Length not stated
- timely reviewsHigh-quality empirical research, brief reports, timely reviews, thought-provoking commentaries, and ongoing discussions of clinical issues will be considered fo…Length not stated
Policy excerpts from the journal's websiteOpen access, Peer review
- Open access Open access
Journal of Dual Diagnosis is a hybrid open access journal that is part of the Taylor & Francis Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the discoverability a…
Source ↗Publisher website ·- Peer review
Rigorous peer review for every open access article Model summary
Rigorous peer review for every open access article
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Taylor & Francis
- ISSN
- 1550-4263
- Electronic ISSN
- 1550-4271
- Latest issue on the website
- Volume 22, Issue 3 (2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Journal of Dual Diagnosis
What CAS zone is Journal of Dual Diagnosis in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Dual Diagnosis is in Zone 4 of Medicine, and in Zone 4 of the minor category Psychiatry / Psychology, Clinical / Substance Abuse. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Dual Diagnosis?
The latest impact factor listed by LetPub is 1.58; CiteScore 3, h-index 45.
How long does peer review take at Journal of Dual Diagnosis?
The publisher reports about 54 days (first decision after review); the journal's website gives an acceptance rate of 39% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Journal of Dual Diagnosis?
According to LetPub and DOAJ records, Journal of Dual Diagnosis is indexed in SSCI and Scopus. The journal's website also lists PubMed, Embase and PsycINFO; that list has not been checked against each database.
Is Journal of Dual Diagnosis open access, and what is the APC?
Journal of Dual Diagnosis is a hybrid journal. For open-access publication: APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .